Federal Circuit Finds Written Description Support for Narrow Claim Range via Disclosure of Broader Ranges, Vacates PTAB Decision

March 15, 2024

Reading Time : 3 min

The Federal Circuit recently vacated a PTAB decision that claims of an “e-cigarette” patent were unpatentable for lack of written description under 35 U.S.C. § 112. The question on appeal was whether a claimed range was adequately supported by the disclosure of broader ranges. In this case, the answer was “yes.”

The patent-at-issue—RAI Strategic Holdings, Inc.’s U.S. Patent No. 10,492,542—generally relates to “electrically powered smoking articles,” or “e-cigarettes.”  In 2020, Philip Morris Products S.A. sought post grant review of the ’542 Patent, asserting (among other grounds) that dependent claims 10 and 27 were invalid for lack of written description. Those claims recited, in relevant part, a “heating member” with “a length of about 75% to about 85% of a length of [a] disposable aerosol forming substance.”

At the PTAB, Philip Morris argued that the claimed range of “about 75% to about 85%” lacked written description support because the specification disclosed only ranges of 75–125%, 80–120%, 85–115% and 90–110%. According to Philip Morris and its expert, those disclosures did not support the claimed range because (1) they were all “substantially narrower” than the claimed range, (2) none of them recited “an upper limit of 85%” as claimed and (3) they all “centered on” 100%, unlike the claim, which centered on 80%. RAI countered that the disclosed ranges of 75–125% and 85–115% together supported the claim because they expressly include “both ends of the claim range,” i.e., 75% and 85%. Nonetheless, the PTAB agreed with Philip Morris and found the claims unpatentable. RAI appealed.

On appeal, the Federal Circuit vacated the PTAB’s decision, concluding that the facts more closely aligned with decisions finding written description support for a claim range. In re Wertheim, for example, held that the disclosure of coffee grounds with “25% to 60%” solid coffee extract supported a claim range of “between 35% and 60%.” 541 F.2d 257 (C.C.P.A. 1976). Importantly, the Wertheim court found no evidence that the “broad described range pertain[ed] to a different invention than the narrower (and subsumed) claimed range.” 

Here, the Federal Circuit likewise saw no evidence—including from Philip Morris’s expert—that the disclosed ranges were “different inventions” than the claimed range. That is, “nothing in the specification indicate[d] that changing the length of the heating member changes the invention, whether as to operability, effectiveness, or any other parameter.” Although the specification did not disclose the claimed range, it did expressly disclose both endpoints of the claimed range. Moreover, the “predictability of electro-mechanical inventions” such as e-cigarettes further supported the Federal Circuit’s ruling, as predictable art requires “a lower level of detail” to satisfy written description than unpredictable art.

The Court also grappled with cases that found a lack of written description on somewhat similar facts, most notably Indivior UK Ltd. v. Dr. Reddy’s Laboratories S.A., 18 F. 4th 1323 (Fed. Cir. 2021). The Indivior claims recited a therapeutic film comprising “about 48.2 wt % to about 58.6 wt %” polymers. The specification, meanwhile, disclosed a table with a 48.2 wt % polymer and a 58.6 wt % polymer—the endpoints of the claimed range. However, unlike the present case, in Indivior, there was a “lack of persuasive evidence that a skilled artisan would have understood the application as disclosing an invention with the range between these endpoints.” The Indivior patent also differed in that it involved an unpredictable art and the specification made “inconsistent statements regarding the desired amount of polymer.”

Finally, in coming to its conclusion, the Federal Circuit repeatedly emphasized that written description is assessed on a case-by-case basis and that “broadly articulated rules are particularly inappropriate in this area.” Instead, one must consider the technology at issue, the predictability of the art, the complexity of the claim limitation and the knowledge gained by a person skilled in the art reading the specification. Thus, while the Court relied on prior cases for support and guidance, its ruling was ultimately “based on the unique facts of this case.”

Practice Tip: Although claims directed to ranges that are not explicitly disclosed in the specification may be susceptible to written description attacks, particularly in arts regarded as unpredictable, the RAI case shows that such claims may be adequately supported if the disclosed and claim ranges are not shown to be “different inventions.” Parties asserting and defending against such attacks should focus arguments on the specific facts of the case and, if possible, provide expert testimony that addresses how exactly the claim range is (or is not) a different invention from the ranges disclosed in the patent.

RAI Strategic Holdings, Inc. v. Philip Morris Products S.A., No. 22-1862 (Fed. Cir. Feb. 9, 2024)

Share This Insight

Previous Entries

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of
products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.
...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal
of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims
were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an
attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.
...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of
the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug
product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and
the related statutory context.
...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition
challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged
claim construction issues or the number, length or scope differences of the challenged claims.
...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the
Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel
litigation. Weighing the factors as a whole, the Director determined that institution should be denied.
...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a
parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB
would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in
view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.
...

Read More

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal
Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to
invalidate claims in district court.
...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s
later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s
patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory
forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.
...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.